Clinical trial · Observational
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
A Real-world Study to Explore Recurrence/Metastases of the Early-stage (I-IIIA) NSCLC Patients and the Impact Factors of Patient Survivals
NCT03710616CI-TRIAL-00039837unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgeries | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease-free survival rates within the configured observation periods
- timeFrame
- 2009-2017
- description
- Disease-free survival rates within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods;
Secondary outcomes (1)
- measure
- Disease-free survival rates at the configured locations and observation periods
- timeFrame
- 2009-2017
- description
- Disease-free survival rates at the metastasized lymph nodes, bone, and brain within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods;
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: The patients who meet all the following inclusion criteria will be included in the study: * The patients who were operated with radical operations of the lung cancer; * The patients with clinical I-IIIA staging tumors; * The pathologically diagnosed NSCLC patients; Exclusion Criteria: \- Not be specified;
References
Publications (0)
Data not yet available
No reference posted for this study.